2,5-Dimethoxy-4-chloroamphetamine

Use and effects

In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists DOC's dose as 1.5 to 3mg orally and its duration as 12 to 24hours. The effects of DOC have been reported to include closed-eye imagery, visuals, introspection, lightheadedness, disconnectedness, and spaciness, among others. In one of the reports, it was described as an "archetypical psychedelic", with the full spectrum of psychedelic effects. This was contrasted with 2C psychedelics, which were described as more subtle and gentle.

Toxicity

Very little data exists about the toxicity of DOC. In April 2013, a case of death due to DOC was reported. The source does not specify whether the drug alone caused the death. In 2014, a death was reported in which DOC was directly implicated as the sole causative agent in the death of a user. The autopsy indicated pulmonary edema and a subgaleal hemorrhage.

Interactions

Pharmacology

Pharmacodynamics

Actions

DOC acts as a serotonin 5-HT2A and 5-HT2C receptor agonist. Its psychedelic effects are mediated via its actions on the 5-HT2A receptor.

The drug is inactive as a monoamine releasing agent and reuptake inhibitor.

Effects

DOC produces the head-twitch response, a behavioral proxy of psychedelic-like effects, in rodents.

DOC has shown reinforcing effects, including conditioned place preference (CPP) and self-administration, in rodents similarly to methamphetamine. This is analogous to other findings in which various 2C and NBOMe drugs have been found to produce dopaminergic elevations and reinforcing effects in rodents. Conversely however, in contrast to amphetamines like (−)-cathinone but similarly to mescaline, DOM has shown no stimulant-like or reinforcing effects in rhesus monkeys.

Chemistry

DOC is a substituted α-methylated phenethylamine, a class of compounds commonly known as amphetamines. The phenethylamine equivalent (lacking the α-methyl group) is 2C-C. DOC has a stereocenter and (R)-(−)-DOC is the more active stereoisomer.

Synthesis

The chemical synthesis of DOC has been described.

Detection

DOC may be quantitated in blood, plasma or urine by gas chromatography-mass spectrometry or liquid chromatography-mass spectrometry to confirm a diagnosis of poisoning in hospitalized patients or to provide evidence in a medicolegal death investigation. Blood or plasma DOC concentrations are expected to be in a range of 1–10 μg/L in persons using the drug recreationally, 20 μg/L in intoxicated patients and 100 μg/L in victims of acute overdosage.

Analogues

Analogues of DOC include DOB, DOI, 2C-C, DODC, and ZDCM-04, among others.

History

DOC was first described in the scientific literature by Ronald Coutts and Jerry Malicky in 1973. Subsequently, it was described in greater detail by Alexander Shulgin in his 1991 book PiHKAL (Phenethylamines i Have Known And Loved).

Society and culture

Popularity

Although rare on the black market, it has been available in bulk and shipped worldwide by select elite "Grey Market" Research Chemical suppliers for several years. Sales of DOC on blotting paper and in capsules was reported in late 2005 and again in late 2007. According to the DEA's Microgram from December 2007, the Concord Police Department in Contra Costa County, California, in the US, seized "a small piece of crudely lined white blotter paper without any design, suspected LSD 'blotter acid'". They added "Unusually, the paper appeared to be hand-lined using two pens, in squares measuring approximately 6 x 6 millimeters. The paper displayed fluorescence when irradiated at 365 nanometers; however, color testing for LSD with para-dimethylaminobenzaldehyde (Ehrlich's reagent) was negative. Analysis of a methanol extract by GC/MS indicated not LSD but rather DOC (not quantitated but a high loading based on the TIC)". DOC is sometimes misrepresented as LSD by unscrupulous dealers. This is particularly dangerous, as DOC is not known to have the safety profile of LSD. It can be particularly unsafe, in comparison to LSD, for those suffering from hypertension, as amphetamine compounds are known to cause sharp increases in systolic blood pressure.

Legal status

International

In December 2019, the UNODC announced scheduling recommendations placing DOC into Schedule I alongside another several research chemicals.

Australia

Unscheduled but can be controlled as schedule II as an analogue of DOB.

Canada

Listed as a Schedule 1 as it is an analogue of amphetamine. The CDSA was updated as a result of the Safe Streets Act changing amphetamines from Schedule 3 to Schedule 1.

China

As of October 2015 DOC is a controlled substance in China.

Denmark

Denmark added DOC to the list of Schedule I controlled substances as of 8.4.2007.

Germany

Scheduled in Anlage I since 22.1.2010.

New Zealand

Scheduled.

Sweden

Sveriges riksdag added DOC to schedule I ("substances, plant materials and fungi which normally do not have medical use") as narcotics in Sweden as of Aug 30, 2007, published by Medical Products Agency in their regulation LVFS 2007:10 listed as DOC, 4-klor-2,5-dimetoxi-amfetamin. DOC was first classified by Sveriges riksdags health ministry Statens folkhälsoinstitut as "health hazard" under the act Lagen om förbud mot vissa hälsofarliga varor (translated Act on the Prohibition of Certain Goods Dangerous to Health) as of Jul 1, 2004, in their regulation SFS 2004:486 listed as 4-klor-2,5-dimetoxiamfetamin (DOC).

United Kingdom

Class A.

United States

DOC is not scheduled or controlled at the federal level in the United States, but the Department of Justice considers it to be an analogue of DOB and, as such, possession or sale could be prosecuted under the Federal Analogue Act. In December 2023, the US Drug Enforcement Administration issued a notice of proposed rulemaking that would classify both 2,5-dimethoxy-4-chloroamphetamine and 2,5-dimethoxy-4-iodoamphetamine as schedule I controlled substances.

In the United States, the analogues DMA, DOB, and DOM are Schedule I controlled substances.

Florida

DOC is a Schedule I controlled substance in the state of Florida making it illegal to buy, sell, or possess.

References

References

1. Anvisa. (2023-07-24). "RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial". [[Diário Oficial da União]].
2. (September 1991). "PiHKAL: A Chemical Love Story". Transform Press.
3. (1 May 1973). "The Synthesis of Some Analogs of the Hallucinogen 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane (DOM)". Canadian Journal of Chemistry.
4. (October 2025). "The Epidemiology of Recreational Use and Availability of DOC and DOI in the United States". Journal of Psychoactive Drugs.
5. (2013-04-25). ""Moment of madness": rare drug implicated in student death". The Saint.
6. (October 2014). "A fatal intoxication of 2,5-dimethoxy-4-chloroamphetamine: a case report". Journal of Analytical Toxicology.
7. "PDSP Database".
8. (1990). "BindingDB BDBM50013000 CHEMBL8100". Journal of Medicinal Chemistry.
9. (March 2014). "Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function". Psychopharmacology (Berl).
10. (2022). "Structure-activity Relation of Halogenated 2,5-Dimethoxyamphetamines Compared to their α‑Desmethyl (2C) Analogues". The FASEB Journal.
11. (May 2020). "Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species". Neuropharmacology.
12. (May 2018). "Rewarding and reinforcing effects of 4-chloro-2,5-dimethoxyamphetamine and AH-7921 in rodents". Neurosci Lett.
13. (June 2025). "Toxicodynamic insights of 2C and NBOMe drugs - Is there abuse potential?". Toxicol Rep.
14. (April 2021). "New designer phenethylamines 2C-C and 2C-P have abuse potential and induce neurotoxicity in rodents". Arch Toxicol.
15. (November 2020). "25B-NBOMe, a novel N-2-methoxybenzyl-phenethylamine (NBOMe) derivative, may induce rewarding and reinforcing effects via a dopaminergic mechanism: Evidence of abuse potential". Addict Biol.
16. (October 2019). "A novel designer drug, 25N-NBOMe, exhibits abuse potential via the dopaminergic system in rodents". Brain Res Bull.
17. (November 2022). "Rewarding and Reinforcing Effects of 25H-NBOMe in Rodents". Brain Sci.
18. (August 2023). "Designer Drug, 25D-NBOMe, Has Reinforcing and Rewarding Effects through Change of a Dopaminergic Neurochemical System". ACS Chem Neurosci.
19. (April 2024). "The novel psychoactive substance 25E-NBOMe induces reward-related behaviors via dopamine D1 receptor signaling in male rodents". Arch Pharm Res.
20. (January 2008). "The behavioral pharmacology of hallucinogens". Biochem Pharmacol.
21. (January 2017). "The serotonin 5-HT2C receptor and the non-addictive nature of classic hallucinogens". J Psychopharmacol.
22. (June 1986). "Intravenous self-administration of (−)-cathinone and 2-amino-1-(2,5-dimethoxy-4-methyl)phenylpropane in rhesus monkeys". Drug Alcohol Depend.
23. (October 2024). "Evaluation of potential punishing effects of 2,5-dimethoxy-4-methylamphetamine (DOM) in rhesus monkeys responding under a choice procedure". Behav Pharmacol.
24. (2014). "Disposition of toxic drugs and chemicals in man". Biomedical Publications.
25. "mg1207".
26. "December 2019 – WHO: World Health Organization recommends 12 NPS for scheduling".
27. "Erowid DOC Vault: Legal Status".
28. (2022-03-31). "Schedule I". Canadian Legal Information Institute.
29. "Controlled Drugs and Substances Act". Canadian Legal Information Institute.
30. "Backgrounder: The Safe Streets and Communities Act Four Components Coming Into Force". Canadian Department of Justice.
31. (27 September 2015). "关于印发《非药用类麻醉药品和精神药品列管办法》的通知". China Food and Drug Administration.
32. "Läkemedelsverkets föreskrifter - LVFS och HSLF-FS | Läkemedelsverket".
33. (27 May 2004). "Förordning om ändring i förordningen (1999:58) om förbud mot vissa hälsofarliga varor".
34. "PART 1308 - Section 1308.11 Schedule I".
35. "DEA Resources, Microgram, October 2007".
36. "Schedules of Controlled Substances: Placement of 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC) in Schedule I".
37. "The 2017 Florida Statutes - Title XLVI - CRIMES - Chapter 893 - DRUG ABUSE PREVENTION AND CONTROL".